FAAH is overexpressed in prostate cancer cell lines and tumor tissues; tumor FAAH immunoreactivity (FAAH-IR) is positively correlated with disease severity for cases with mid-range CB1 expression [128]. This evidence concerns the gene FAAH and prostate carcinoma.